133 related articles for article (PubMed ID: 21568892)
21. A salicylic acid-based analogue discovered from virtual screening as a potent inhibitor of human 20alpha-hydroxysteroid dehydrogenase.
Dhagat U; Carbone V; Chung RP; Matsunaga T; Endo S; Hara A; El-Kabbani O
Med Chem; 2007 Nov; 3(6):546-50. PubMed ID: 18045204
[TBL] [Abstract][Full Text] [Related]
22. New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3.
Stefane B; Brozic P; Vehovc M; Rizner TL; Gobec S
Eur J Med Chem; 2009 Jun; 44(6):2563-71. PubMed ID: 19237229
[TBL] [Abstract][Full Text] [Related]
23. AKR1C enzymes sustain therapy resistance in paediatric T-ALL.
Bortolozzi R; Bresolin S; Rampazzo E; Paganin M; Maule F; Mariotto E; Boso D; Minuzzo S; Agnusdei V; Viola G; Te Kronnie G; Cazzaniga G; Basso G; Persano L
Br J Cancer; 2018 Apr; 118(7):985-994. PubMed ID: 29515258
[TBL] [Abstract][Full Text] [Related]
24. Selective and potent inhibitors of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1) that metabolizes neurosteroids derived from progesterone.
Higaki Y; Usami N; Shintani S; Ishikura S; El-Kabbani O; Hara A
Chem Biol Interact; 2003 Feb; 143-144():503-13. PubMed ID: 12604236
[TBL] [Abstract][Full Text] [Related]
25. Sex hormones reduce NNK detoxification through inhibition of short-chain dehydrogenases/reductases and aldo-keto reductases in vitro.
Stapelfeld C; Maser E
Chem Biol Interact; 2017 Oct; 276():167-173. PubMed ID: 28257955
[TBL] [Abstract][Full Text] [Related]
26. Retinaldehyde is a substrate for human aldo-keto reductases of the 1C subfamily.
Ruiz FX; Porté S; Gallego O; Moro A; Ardèvol A; Del Río-Espínola A; Rovira C; Farrés J; Parés X
Biochem J; 2011 Dec; 440(3):335-44. PubMed ID: 21851338
[TBL] [Abstract][Full Text] [Related]
27. Promiscuity and diversity in 3-ketosteroid reductases.
Penning TM; Chen M; Jin Y
J Steroid Biochem Mol Biol; 2015 Jul; 151():93-101. PubMed ID: 25500069
[TBL] [Abstract][Full Text] [Related]
28. Structure-guided design, synthesis, and evaluation of salicylic acid-based inhibitors targeting a selectivity pocket in the active site of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1).
El-Kabbani O; Scammells PJ; Gosling J; Dhagat U; Endo S; Matsunaga T; Soda M; Hara A
J Med Chem; 2009 May; 52(10):3259-64. PubMed ID: 19397269
[TBL] [Abstract][Full Text] [Related]
29. Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members.
O'connor T; Ireland LS; Harrison DJ; Hayes JD
Biochem J; 1999 Oct; 343 Pt 2(Pt 2):487-504. PubMed ID: 10510318
[TBL] [Abstract][Full Text] [Related]
30. Discovery of new inhibitors of aldo-keto reductase 1C1 by structure-based virtual screening.
Brozic P; Turk S; Lanisnik Rizner T; Gobec S
Mol Cell Endocrinol; 2009 Mar; 301(1-2):245-50. PubMed ID: 18765269
[TBL] [Abstract][Full Text] [Related]
31. Phytoestrogens as inhibitors of the human progesterone metabolizing enzyme AKR1C1.
Brozic P; Smuc T; Gobec S; Rizner TL
Mol Cell Endocrinol; 2006 Oct; 259(1-2):30-42. PubMed ID: 16962702
[TBL] [Abstract][Full Text] [Related]
32. 2,3-Diarylpropenoic acids as selective non-steroidal inhibitors of type-5 17β-hydroxysteroid dehydrogenase (AKR1C3).
Gazvoda M; Beranič N; Turk S; Burja B; Kočevar M; Rižner TL; Gobec S; Polanc S
Eur J Med Chem; 2013 Apr; 62():89-97. PubMed ID: 23353746
[TBL] [Abstract][Full Text] [Related]
33. Structure-function of human 3 alpha-hydroxysteroid dehydrogenases: genes and proteins.
Penning TM; Jin Y; Steckelbroeck S; Lanisnik Rizner T; Lewis M
Mol Cell Endocrinol; 2004 Feb; 215(1-2):63-72. PubMed ID: 15026176
[TBL] [Abstract][Full Text] [Related]
34. 17β-Hydroxysteroid dehydrogenases (17β-HSDs) as therapeutic targets: protein structures, functions, and recent progress in inhibitor development.
Marchais-Oberwinkler S; Henn C; Möller G; Klein T; Negri M; Oster A; Spadaro A; Werth R; Wetzel M; Xu K; Frotscher M; Hartmann RW; Adamski J
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):66-82. PubMed ID: 21193039
[TBL] [Abstract][Full Text] [Related]
35. Design and validation of specific inhibitors of 17beta-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis.
Day JM; Tutill HJ; Purohit A; Reed MJ
Endocr Relat Cancer; 2008 Sep; 15(3):665-92. PubMed ID: 18541621
[TBL] [Abstract][Full Text] [Related]
36. Tibolone is metabolized by the 3alpha/3beta-hydroxysteroid dehydrogenase activities of the four human isozymes of the aldo-keto reductase 1C subfamily: inversion of stereospecificity with a delta5(10)-3-ketosteroid.
Steckelbroeck S; Jin Y; Oyesanmi B; Kloosterboer HJ; Penning TM
Mol Pharmacol; 2004 Dec; 66(6):1702-11. PubMed ID: 15383625
[TBL] [Abstract][Full Text] [Related]
37. Structural importance of the C-terminal region in pig aldo-keto reductase family 1 member C1 and their effects on enzymatic activity.
Son M; Park C; Kwon SG; Bang WY; Kim SW; Kim CW; Lee KW
BMC Struct Biol; 2015 Jan; 15():1. PubMed ID: 25583233
[TBL] [Abstract][Full Text] [Related]
38. Mefenamic acid enhances anticancer drug sensitivity via inhibition of aldo-keto reductase 1C enzyme activity.
Shiiba M; Yamagami H; Yamamoto A; Minakawa Y; Okamoto A; Kasamatsu A; Sakamoto Y; Uzawa K; Takiguchi Y; Tanzawa H
Oncol Rep; 2017 Apr; 37(4):2025-2032. PubMed ID: 28259989
[TBL] [Abstract][Full Text] [Related]
39. Long-chain fatty acids inhibit human members of the aldo-keto reductase 1C subfamily.
Hara A; Endo S; Matsunaga T; Soda M; Yashiro K; El-Kabbani O
J Biochem; 2017 Nov; 162(5):371-379. PubMed ID: 28992312
[TBL] [Abstract][Full Text] [Related]
40. [Correlation of aldo-keto reductases with prostate cancer and intervention with traditional Chinese medicine].
Chen HJ; Chen ZJ; DU GL
Zhonghua Nan Ke Xue; 2019 Aug; 25(8):734-738. PubMed ID: 32227718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
